TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Short Interest Update

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) was the target of a large growth in short interest in December. As of December 15th, there was short interest totalling 57,600 shares, a growth of 22.8% from the November 30th total of 46,900 shares. Based on an average daily volume of 35,900 shares, the days-to-cover ratio is currently 1.6 days. Currently, 1.7% of the company’s shares are sold short.

Wall Street Analysts Forecast Growth

TLSI has been the subject of a number of analyst reports. Northland Securities started coverage on shares of TriSalus Life Sciences in a research note on Friday, October 25th. They set an “outperform” rating and a $12.50 target price for the company. Roth Capital raised TriSalus Life Sciences to a “strong-buy” rating in a report on Monday, November 11th. Cantor Fitzgerald assumed coverage on TriSalus Life Sciences in a research report on Tuesday, December 17th. They issued an “overweight” rating and a $10.00 price target for the company. Oppenheimer initiated coverage on shares of TriSalus Life Sciences in a research note on Monday, September 16th. They set an “outperform” rating and a $10.00 price objective for the company. Finally, Northland Capmk upgraded shares of TriSalus Life Sciences to a “strong-buy” rating in a research note on Friday, October 25th. Seven analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, TriSalus Life Sciences currently has a consensus rating of “Buy” and a consensus target price of $11.79.

Insiders Place Their Bets

In other news, major shareholder Equity Ab Frankenius bought 62,972 shares of the stock in a transaction dated Tuesday, December 17th. The stock was bought at an average price of $3.97 per share, for a total transaction of $249,998.84. Following the purchase, the insider now directly owns 6,230,748 shares in the company, valued at $24,736,069.56. This trade represents a 1.02 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last ninety days, insiders purchased 70,012 shares of company stock worth $281,235. 32.80% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On TriSalus Life Sciences

A number of institutional investors and hedge funds have recently modified their holdings of the company. Highbridge Capital Management LLC purchased a new position in shares of TriSalus Life Sciences in the second quarter worth approximately $1,184,000. Duquesne Family Office LLC boosted its stake in shares of TriSalus Life Sciences by 35.1% during the 2nd quarter. Duquesne Family Office LLC now owns 426,921 shares of the company’s stock worth $2,357,000 after acquiring an additional 110,966 shares during the last quarter. Geode Capital Management LLC grew its position in shares of TriSalus Life Sciences by 45.4% during the 3rd quarter. Geode Capital Management LLC now owns 200,427 shares of the company’s stock valued at $924,000 after acquiring an additional 62,542 shares during the period. Wolverine Asset Management LLC bought a new stake in shares of TriSalus Life Sciences during the 2nd quarter valued at $240,000. Finally, MSD Partners L.P. purchased a new stake in shares of TriSalus Life Sciences in the 3rd quarter worth $184,000. 2.58% of the stock is currently owned by hedge funds and other institutional investors.

TriSalus Life Sciences Trading Up 2.5 %

NASDAQ:TLSI opened at $4.96 on Tuesday. The company has a market cap of $151.25 million, a PE ratio of -1.99 and a beta of 0.56. The company has a 50 day simple moving average of $4.19 and a two-hundred day simple moving average of $4.84. TriSalus Life Sciences has a 12 month low of $3.50 and a 12 month high of $10.42.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.